| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 |
| 25 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underw... |
| 22 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
TSHA-102 Rett Syndrome program Update: Longer-term Results from REVEAL Phase 1/2 trials June 2026 Exhibit 99.2 |
| 02 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 1, 2026, Taysha Gene Therapies, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders considered four proposals, each of which is described in more detai... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 |
| 04 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials... |
| 16 Oct 2025 |
8-K: Other Events
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome |
| 09 Oct 2025 |
8-K: Other Events
Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced review by independent centra... |
| 02 Oct 2025 |
8-K: Other Events
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipate... |
| 03 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Taysha Gene Therapies, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: |
| 29 May 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underw... |
| 28 May 2025 |
8-K: Regulation FD Disclosure; Other Events
This presentation is intended to be viewed by investors in the U.S. only Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, ... |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition
Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related |
| 13 Nov 2024 |
8-K: Results of Operations and Financial Condition
High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (high dose) across both REVEAL trials; ei... |
| 12 Aug 2024 |
8-K: Results of Operations and Financial Condition
Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 5... |
| 26 Jun 2024 |
8-K: Entry into a Material Definitive Agreement; Other Events
Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underw... |
Loading...